NO20032482D0 - Compounds specific for adenosine A1, A2A and A <N> 3 receptor, and use thereof - Google Patents

Compounds specific for adenosine A1, A2A and A <N> 3 receptor, and use thereof

Info

Publication number
NO20032482D0
NO20032482D0 NO20032482A NO20032482A NO20032482D0 NO 20032482 D0 NO20032482 D0 NO 20032482D0 NO 20032482 A NO20032482 A NO 20032482A NO 20032482 A NO20032482 A NO 20032482A NO 20032482 D0 NO20032482 D0 NO 20032482D0
Authority
NO
Norway
Prior art keywords
adenosine
receptor
compounds specific
compounds
specific
Prior art date
Application number
NO20032482A
Other languages
Norwegian (no)
Other versions
NO20032482L (en
NO327207B1 (en
Inventor
Arlindo Lucas Castelhano
Bryan Mckibben
David J Witter
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/728,607 external-priority patent/US6664252B2/en
Priority claimed from US09/728,316 external-priority patent/US6680322B2/en
Priority claimed from US09/728,616 external-priority patent/US7160890B2/en
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of NO20032482D0 publication Critical patent/NO20032482D0/en
Publication of NO20032482L publication Critical patent/NO20032482L/en
Publication of NO327207B1 publication Critical patent/NO327207B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20032482A 2000-12-01 2003-06-02 Compounds specific for adenosine A1, A2A and A3 receptor as well as their use in the preparation of drugs and methods for the preparation of the compounds NO327207B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/728,607 US6664252B2 (en) 1999-12-02 2000-12-01 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US09/728,316 US6680322B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A1 receptors and uses thereof
US09/728,616 US7160890B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A3 receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (en) 2000-12-01 2001-11-30 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (3)

Publication Number Publication Date
NO20032482D0 true NO20032482D0 (en) 2003-06-02
NO20032482L NO20032482L (en) 2003-07-28
NO327207B1 NO327207B1 (en) 2009-05-11

Family

ID=27419112

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032482A NO327207B1 (en) 2000-12-01 2003-06-02 Compounds specific for adenosine A1, A2A and A3 receptor as well as their use in the preparation of drugs and methods for the preparation of the compounds

Country Status (20)

Country Link
EP (1) EP1347980A4 (en)
JP (1) JP4579497B2 (en)
CN (1) CN1263757C (en)
AP (1) AP1893A (en)
AU (1) AU2002248151B2 (en)
BR (1) BR0115847A (en)
CA (1) CA2430577A1 (en)
CZ (1) CZ20031831A3 (en)
EA (1) EA007254B1 (en)
HU (1) HUP0400692A3 (en)
IL (1) IL155962A0 (en)
ME (1) MEP35308A (en)
MX (1) MXPA03004717A (en)
NO (1) NO327207B1 (en)
NZ (1) NZ525885A (en)
OA (1) OA13295A (en)
PL (1) PL363245A1 (en)
WO (1) WO2002057267A1 (en)
YU (1) YU42703A (en)
ZA (1) ZA200303729B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5090531A (en) * 1990-01-10 1992-02-25 Lord Corporation Electrophoretic fluid differential
HUP0103836A3 (en) 1998-06-02 2003-05-28 Osi Pharmaceuticals Inc Uniond Pyrrolo[2,3d]pyrimidine compositions and their use
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (en) * 2001-10-04 2003-04-10 Merck Patent Gmbh New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors
EP2050751A1 (en) 2001-11-30 2009-04-22 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
JP2005516005A (en) * 2001-12-07 2005-06-02 バーテクス ファーマスーティカルズ インコーポレイテッド Pyrimidine-based compounds useful as GSK-3 inhibitors
DE60236458D1 (en) 2001-12-20 2010-07-01 Osi Pharm Inc PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONISTIC COMPOUNDS, THEIR SYNTHESIS AND USE
EP1465631B1 (en) 2001-12-20 2010-02-24 OSI Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
US7199119B2 (en) * 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (en) 2004-10-25 2006-05-31 Astex Therapeutics Ltd SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES
ES2878130T3 (en) 2006-04-25 2021-11-18 Astex Therapeutics Ltd Derivatives of purine and deazapurine as pharmaceutical compounds
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
BRPI0818533B8 (en) 2007-10-11 2021-05-25 Astrazeneca Ab compound, pharmaceutical composition, use of a compound, and, process for preparing a compound
US8349847B2 (en) 2008-01-11 2013-01-08 Durga Prasad Konakanchi Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents
AR070127A1 (en) 2008-01-11 2010-03-17 Novartis Ag PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
RS59568B1 (en) 2011-04-01 2019-12-31 Astrazeneca Ab Therapeutic treatment
EP2785349B2 (en) 2011-11-30 2022-11-09 Astrazeneca AB Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
MX2014014832A (en) * 2012-06-07 2015-02-12 Hoffmann La Roche Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase.
BR112015031073B1 (en) 2013-06-21 2022-11-29 Zenith Epigenetics Ltd BICYCLIC BROMODIMANIUM INHIBITORS AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS
CN105473581B (en) * 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 The dicyclic compound newly replaced as bromine structural domain inhibitor
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
EP3230277B1 (en) 2014-12-11 2019-09-18 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
WO2016097863A1 (en) 2014-12-17 2016-06-23 Zenith Epigenetics Corp. Inhibitors of bromodomains
EA036122B1 (en) * 2015-01-20 2020-09-30 Уси Форчун Фармасьютикал Ко., Лтд Jak inhibitor
PT3290418T (en) 2015-04-29 2019-07-16 Wuxi Fortune Pharmaceutical Co Ltd Janus kinase (jak) inhibitors
EP3305788B1 (en) 2015-05-29 2020-08-05 Wuxi Fortune Pharmaceutical Co., Ltd Janus kinase inhibitor
CN105771672B (en) * 2016-04-18 2018-03-02 天津工业大学 A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method
CN108570054B (en) * 2017-03-07 2021-07-16 广州再极医药科技有限公司 Aminopyrimidine five-membered heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application
CN108017584B (en) * 2017-06-20 2021-03-23 南开大学 A3Small molecule antagonists of adenosine receptors
EP3802540A1 (en) * 2018-06-04 2021-04-14 Exscientia Ltd Pyrazolopyrimidine compounds as adenosine receptor antagonists
CN110128316B (en) * 2019-05-22 2021-08-31 北京大学深圳研究生院 Preparation method of 5-substituted beta-proline and derivatives thereof
CN110272373B (en) * 2019-07-02 2022-07-29 天津国际生物医药联合研究院 Selective adenosine A 1 Receptor antagonists and uses thereof
CN114085178A (en) * 2021-12-29 2022-02-25 苏州楚凯药业有限公司 Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286892B6 (en) * 1992-12-17 2000-07-12 Pfizer Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
HUP0103836A3 (en) * 1998-06-02 2003-05-28 Osi Pharmaceuticals Inc Uniond Pyrrolo[2,3d]pyrimidine compositions and their use
ES2269217T3 (en) * 1999-12-02 2007-04-01 Osi Pharmaceuticals, Inc. SPECIFIC COMPOUNDS FOR ADENOSINE A1, A2A AND A3 RECEPTORS AND THEIR USES.
EP2050751A1 (en) * 2001-11-30 2009-04-22 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof

Also Published As

Publication number Publication date
AU2002248151B2 (en) 2008-02-21
PL363245A1 (en) 2004-11-15
HUP0400692A2 (en) 2004-07-28
EA200300628A1 (en) 2003-12-25
EA007254B1 (en) 2006-08-25
EP1347980A4 (en) 2005-02-09
CN1263757C (en) 2006-07-12
AP2003002807A0 (en) 2003-06-30
CZ20031831A3 (en) 2004-05-12
IL155962A0 (en) 2003-12-23
MXPA03004717A (en) 2004-06-30
JP2004517896A (en) 2004-06-17
EP1347980A1 (en) 2003-10-01
NZ525885A (en) 2005-01-28
WO2002057267A1 (en) 2002-07-25
ZA200303729B (en) 2004-05-14
CN1489590A (en) 2004-04-14
MEP35308A (en) 2011-02-10
NO20032482L (en) 2003-07-28
AP1893A (en) 2008-09-23
HUP0400692A3 (en) 2007-09-28
CA2430577A1 (en) 2002-07-25
YU42703A (en) 2006-03-03
NO327207B1 (en) 2009-05-11
OA13295A (en) 2007-04-13
BR0115847A (en) 2004-02-25
JP4579497B2 (en) 2010-11-10

Similar Documents

Publication Publication Date Title
NO20032482L (en) Compounds specific for adenosine A1, A2A and A &lt;N&gt; 3 receptor, and use thereof
PT1056759E (en) 2- (PURIN-9-YL) -TETRAHYDROFURANE-3,4-DIOLE DERIVATIVES
ATE256141T1 (en) N-PYRAZOLE A2A RECEPTOR AGONISTS
DE60002722D1 (en) C-PYRAZOLE A2A RECEPTOR AGONISTS
MA26878A1 (en) ADENOSINE RECEPTOR REGULATORS
NO20032735L (en) Diphenyllazetidinone derivatives, process for their preparation, drugs containing these compounds and their use
EE200000441A (en) 2- (purin-9-yl) tetrahydrofuran-3,4-diol derivatives
DE60110219D1 (en) ADENOSINE A2A RECEPTOR ANTAGONISTS
NO20022573D0 (en) N6 heterocyclic, 8-modified adenosine derivatives
MXPA03000078A (en) Purine derivatives.
PT1192170E (en) PROPARGILFENILETER A2A RECEPTOR AGONISTS
DE60209251D1 (en) ADENOSINE A2A RECEPTOR ANTAGONISTS
DE69934814D1 (en) NON-CIRCULAR MICRO-DRILLING
NO20032483L (en) Condensed purine derivatives as A &lt;N&gt; 1 &lt;N /&gt; - adenosine receptor antagonists
ID28539A (en) IMIDAZO (1,2A) AZINA SUBSTITUTED AS A COX-2 SELECTIVE HOLDER
AU2001247227A1 (en) 2-thioether a2a receptor agonists
ATE308460T1 (en) TRANSFER MECHANISM
IT247521Y1 (en) PANIC HANDLE.
IT247441Y1 (en) PANIC HANDLE.
GB0010292D0 (en) A adenosine receptor agonists
IT1308149B1 (en) MODIFIED TOOL HOLDER.
ES1030353Y (en) HAND FOR MORTAR, IMPROVED.
ZA200204153B (en) Compounds specific to adenosine A3, A2A, and A3 receptor and uses thereof.
ES1040494Y (en) ISOTHERMIC BAG FOR BOTTLES.
ES1041367Y (en) DEVICE FOR HOLDING PANELS.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees